The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis
- 15 December 2010
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 18 (1), 69-77
- https://doi.org/10.1111/j.1468-1331.2010.03110.x
Abstract
Background: Most disease‐modifying therapies (DMTs) for multiple sclerosis (MS) are self‐injectable medications that must be taken on an ongoing basis to reduce disease activity. Thus, adherence to therapy becomes an important challenge that must be addressed to maximize benefits of therapy. This study evaluated rates of adherence to prescribed treatment and explored factors affecting adherence amongst patients with relapsing‐remitting MS. Methods: This was an observational, multicenter, multinational, phase 4 study. Patients and physicians received paper questionnaires regarding adherence to DMTs approved at the time of the study, including intramuscular interferon beta‐1a (IFNβ‐1a), subcutaneous IFNβ‐1a, IFNβ‐1b, and glatiramer acetate. Quality of life and cognition data also were collected. Multivariate analysis was conducted to identify factors associated with adherence to long‐term DMTs. Results: Two thousand six hundred and forty‐eight patients were studied, revealing an average treatment duration of 31 months. Seventy‐five percent of patients (n = 1923) were adherent to therapy. The most common reasons for non‐adherence were forgetting to administer the injection (50.2%) and other injection‐related reasons (32.0%). Adherent patients reported better quality of life (P < 0.05) and fewer neuropsychological issues (P < 0.001) than non‐adherent patients. Adherent patients had significantly shorter duration of disease (P < 0.001) and shorter duration of therapy (P = 0.005) than non‐adherent patients. Women were more likely than men to adhere to treatment. Conclusion: Identifying factors that affect adherence to prescribed treatments is the first step in improving adherence of patients with MS to therapy, thereby helping maximize the benefits of long‐term DMTs.Keywords
This publication has 24 references indexed in Scilit:
- Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosisEuropean Journal of Neurology, 2006
- Long-term interferon-β treatment for multiple sclerosisNeurological Sciences, 2003
- Interrupted therapyNeurology, 2003
- Adherence to Disease-Modifying Therapy in Multiple Sclerosis: Part IRehabilitation Nursing Journal, 2001
- Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosisMultiple Sclerosis Journal, 1999
- Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-laMultiple Sclerosis Journal, 1998
- Depression and multiple sclerosisNeurology, 1996
- Disease Steps in multiple sclerosisNeurology, 1995
- Cognitive dysfunction in multiple sclerosis.Neurology, 1991
- Memory impairment in multiple sclerosisJournal of Clinical and Experimental Neuropsychology, 1990